KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EBITDA (2016 - 2025)

Eli Lilly (LLY) has disclosed EBITDA for 17 consecutive years, with $8.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 66.8% year-over-year to $8.9 billion, compared with a TTM value of $29.2 billion through Dec 2025, up 80.56%, and an annual FY2025 reading of $29.2 billion, up 80.56% over the prior year.
  • EBITDA was $8.9 billion for Q4 2025 at Eli Lilly, up from $8.0 billion in the prior quarter.
  • Across five years, EBITDA topped out at $8.9 billion in Q4 2025 and bottomed at $1.4 billion in Q2 2021.
  • Average EBITDA over 5 years is $3.6 billion, with a median of $2.6 billion recorded in 2022.
  • The sharpest move saw EBITDA tumbled 37.78% in 2023, then skyrocketed 101.06% in 2025.
  • Year by year, EBITDA stood at $2.4 billion in 2021, then decreased by 13.08% to $2.1 billion in 2022, then surged by 44.94% to $3.0 billion in 2023, then soared by 77.35% to $5.3 billion in 2024, then surged by 66.8% to $8.9 billion in 2025.
  • Business Quant data shows EBITDA for LLY at $8.9 billion in Q4 2025, $8.0 billion in Q3 2025, and $7.0 billion in Q2 2025.